Epidemiology of chronic myeloid leukaemia (CML)

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 295-302

  Rohrbacher, Maren ^a   Hasford, Joerg ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

chronic myeloid leukaemia (CML); clinical trials and practice; epidemiology; health care; incidence; Philadelphia (Ph) BCR ABL positive; prevalence

Indexed keywords

ALPHA INTERFERON; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER INCIDENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; ETHNIC DIFFERENCE; GEOGRAPHY; HUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME;

DISEASE MANAGEMENT; GUIDELINE ADHERENCE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PRACTICE GUIDELINES AS TOPIC;

EID: 71849094801     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.07.007     Document Type: Article

References (42)

1. Hehlmann R., Hochhaus A., and Baccarani M. Chronic myeloid leukaemia. Lancet 370 (2007) 342-350
2. Parkin D.M. The evolution of the population-based cancer registry. Nat Rev Cancer 6 (2006) 603-612
3. Swedish Cancer Registry. Annual report publications of the centre of epidemiology at the National Board of Health and Welfare. Available from: (1998-2006). http://www.socialstyrelsen.se/Statistik/statistik_amne/Cancer
4. Krebsregister Saarland, Germany. Available from:. http://www.krebsregister.saarland.de
5. Ries L.A.G., Melbert D., Krapcho M., et al. SEER cancer statistics review. Available from: (1975-2005), U.S. National Cancer Institute, Bethesda. http://www.seer.cancer.gov/csr/1975_2005
6. Micheli A., Coebergh J.W., Mugno E., et al. European health systems and cancer care. Ann Oncol 14 Suppl. 5 (2003) v41-v60
7. Phekoo K.J., Richards M.A., Moller H., et al. The incidence and outcome of myeloid malignancies in 2112 adult patients in southeast-England. Haematologica- Hematol J 91 (2006) 1400-1404
8. Harrison S.J., Johnson P.R.E., and Holyoake T.L. The Scotland leukaemia registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49 (2004) 87-90
9. McNally R.J., Rowland D., Roman E., et al. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15 (1997) 173-189
10. Rohrbacher M., Berger U., Hochhaus A., et al. Clinical trials underestimate age of chronic myeloid leukemia (CML) Patients. Incidence and median age of Ph/BCR-ABL positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23 (2008) 602-604
11. Hasford J., Tauscher M., Hochhaus A., et al. Incidence, co-morbidity and treatment survey of chronic myeloid leukemia in Germany. (ASH Annual Meeting Abstracts). Blood 110 (2007) [Abstract 2964]
12. Corm S., Micol J., Leroyer A., et al. Kinetic of chronic myeloid leukaemia (CML) prevalence in Northern France since the introduction of imatinib. J Clin Oncol 26 (2008) [May 20 Suppl; Abstract 7088]
13. Ahmad O., Boschi-Pinto C., Lopez A., et al. Age standardization of rates: a new WHO standard. GPE discussion paper series: no. 31. Available from:. http://www.who.int/infobase/help [accessed 08.04.08]
14. Ridell B., Carneskog J., Wedel H., et al. Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983-1992. Eur J Haematol 65 (2000) 267-271
15. Hasford J., Baccarani M., Hehlmann R., et al. Interferon-a and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-a. Blood 88 (1996) 5384-5391
16. Allan N.C., Richards S.M., and Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's working parties for therapeutic trials in adult leukaemia. Lancet 345 (1995) 1392-1397
17. Micheli A., Mugno E., Krogh V., et al. Cancer prevalence in European registry areas. Ann Oncol 13 (2002) 840-865
18. Tardieu S., Brun-Strang C., Berthaud P., et al. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14 (2005) 545-553
19. Verdecchia A., Baili P., Quaglia A., et al. Patient survival for all cancers combined as indicator of cancer control in Europe. Eur J Public Health 18 (2008) 527-532
20. Micheli A., Capocaccia R., Martinez C., et al. Cancer control in Europe: a proposed set of European cancer health indicators. Eur J Public Health 13 (2003) 116-118
21. Baccarani M., Saglio G., Goldman J., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
22. Kantarjian H.M., Cortes J., Guilhot F., et al. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer 109 (2007) 1365-1375
23. Michallet M., Morra E., Steegmann J., et al. Imatinib resistance and/or intolerance in clinical practice in Europe: the "Unmet needs in CML and Ph + ALL" (UNIC) study. (ASH Annual Meeting Abstracts). Blood 110 (2007) [Abstract 1951]
24. Morra E., Michallet M., Steegmann J., et al. Real-life rates of disease monitoring in clinical practice in Europe: the "Unmet needs in CML and Ph + ALL" (UNIC) Study. (ASH Annual Meeting Abstracts). Blood 110 (2007) [Abstract 1959]
25. "It`s best to test" survey: an assessment of CML monitoring across Europe. This survey was conducted between November 2007 and February 2008 by the independent market research agency TNS and funded by Bristol-Myers Squibb. Bristol-Myers Squibb, 2008.
26. Cortes J., Talpaz M., O'Brien S., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98 (2003) 1105-1113
27. Rosti G., Iacobucci I., Bassi S., et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. Haematologica 92 (2007) 101-105
28. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 84 (1994) 4064-4077
29. Baccarani M., Rosti G., De Vivo A., et al. A randomized study of interferon-alpha versus interferon-alpha and low- dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
30. Bonifazi F., De Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
31. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
32. Guilhot F., Chastang C., Michallet M., et al. Interferon alpha2b (IFN) combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337 (1997) 223-229
33. Hasford J., Pfirrmann M., Hehlmann R., et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 90 (1998) 850-858
34. Hehlmann R., Berger U., Pfirrmann M., et al. Randomized comparison of Interferon-a and Hydroxyurea with Hydroxyurea monotherapy in Chronic Myeloid Leukemia (CML-Study II): prolongation of survival by the combination of Interferon-a and Hydroxyurea. Leukemia 17 (2003) 1529-1537
35. Hehlmann R., Berger U., Pfirrmann M., et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 109 (2007) 4686-4692
36. Ohnishi K., Ohno R., Tomonaga M., et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86 (1995) 906-916
37. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820-825
38. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-a2b for chronic myeloid leukemia. Blood 91 (1998) 2713-2721
39. Kluin-Nelemans H.C., Buck G., Le Cessie S., et al. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood 103 (2004) 4408-4415
40. Kantarjian H.M., Talpaz M., O'Brien S., et al. Survival benefit with imatinib mesylate versus interferon alpha-based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood 108 (2006) 1835-1840
41. Xie Y., Davies S.M., Xiang Y., et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 97 (2003) 2229-2235
42. Berger U., Maywald O., Pfirrmann M., et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia 19 (2005) 984-989